Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | NPY1R | P25929 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1737016 | 1.00 | MLNR (0.50) | MLNRADRB2ADRB1HTR1AADRA2A | |
| SCHEMBL29395058 | 1.00 | MLNR (0.50) | MLNRADRB2ADRB1HTR1AADRA2A | |
| SCHEMBL30585650 | 1.00 | MLNR (0.50) | MLNRADRB2ADRB1HTR1AADRA2A | |
| SCHEMBL13925775 | 1.00 | MLNR (0.50) | MLNRADRB2ADRB1HTR1AADRA2A | |
| SCHEMBL1735559 | 1.00 | MLNR (0.50) | MLNRADRB2ADRB1HTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL3905269 | 0.98 | MLNR (0.49) | MLNRADRB2ADRB1HTR1AADRA2A | |
| SCHEMBL26413056 | 0.88 | MLNR (0.50) | MLNRADRB2ADRB1HTR1AADRA2A | |
| SCHEMBL5504949 | 0.86 | HPGD (0.41) | MLNRADRB2ADRB1HTR1AADRA2A | |
| SCHEMBL13766519 | 0.86 | MLNR (0.49) | MLNRADRB2ADRB1HTR1AADRA2A | |
| SCHEMBL3905266 | 0.86 | DRD2 (0.49) | MLNRADRB2ADRB1HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120060394-A | Nebivolol Process for the preparation of Er | 苏州正济医药研究有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-118638090-A | Preparation method of 6-fluorochroman-2-carboxylic acid | 江苏八巨药业有限公司 | 2024-09-13 | — | — | CN | claimed |
| CN-118373795-A | Continuous flow preparation process of chloroketone | 济南立德医药技术有限公司 | 2024-07-23 | — | — | CN | claimed |
| CN-114149956-B | Escherichia coli genetically engineered bacterium for expressing esterase EstR and application thereof | 华东理工大学 | 2024-04-09 | — | — | CN | claimed |
| CN-114214261-B | Escherichia coli genetically engineered bacterium for expressing esterase EstS and application thereof | 华东理工大学 | 2024-04-09 | — | — | CN | claimed |
| CN-114150036-B | Continuous biphasic batch resolution process for preparing optically pure 6-fluoro-chroman-2-carboxylic acid | 华东理工大学 | 2024-01-09 | — | — | CN | claimed |
| CN-114214261-A | Escherichia coli genetic engineering bacterium for expressing esterase EstS and application thereof | 华东理工大学 | 2022-03-22 | — | — | CN | claimed |
| CN-114149956-A | Escherichia coli genetic engineering bacterium for expressing esterase EstR and application thereof | 华东理工大学 | 2022-03-08 | — | — | CN | claimed |
| CN-114150036-A | Continuous two-phase batch resolution process for preparing optically pure 6-fluoro-chroman-2-carboxylic acid | 华东理工大学 | 2022-03-08 | — | — | CN | claimed |
| CN-110791488-A | Lipase for splitting chiral compound and preparation method and application thereof | 西南交通大学 | 2020-02-14 | — | — | CN | claimed |
| WO-2016185492-A1 | PROCESS FOR PREPARATION OF NEBIVOLOL AND IT'S SALTS | IPCA LABORATORIES LIMITED (IN) | 2016-11-24 | — | — | WO | claimed |
| US-20110250454-A1 | PREPARATION OF NEBIVOLOL | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-10-13 | — | — | US | claimed |
| WO-2010089764-A2 | IMPROVED PROCESS FOR THE PREPARATION OF NEBIVOLOL HYDROCHLORIDE | MSN LABORATORIES LIMITED (IN) | 2010-08-12 | — | — | WO | claimed |
| CN-100491365-C | Process of racemizing 6-fluoro-3,4-dihydro-2H-1-benzopyran-2-formic acid | UNIV ZHEJIANG (CN) | 2009-05-27 | — | — | CN | claimed |
| CN-101020681-A | Synthesis process of 6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol | UNIV ZHEJIANG (CN) | 2007-08-22 | — | — | CN | claimed |
| CN-1974565-A | Process of racemizing 6-fluoro-3,4-dihydro-2H-1-benzopyran-2-formic acid | UNIV ZHEJIANG (CN) | 2007-06-06 | — | — | CN | claimed |
| EP-3704090-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-120060394-A | Nebivolol Process for the preparation of Er | 苏州正济医药研究有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-4654362-A | CARDIOVASCULAR DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1987-03-31 | — | — | US | disclosed |
| EP-0145067-A2 | Derivatives of 2,2'-iminobisethanol | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250454-A1 | PREPARATION OF NEBIVOLOL | ADRB2, ADRB1, ADRA2B | MLNR 695/4885ADRB2 1/4885ADRB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.